Non-disclosure of drug injection practices as a barrier to HCV testing: results from the PrebupIV community-based research study

Harm Reduction Journal

Research

Michels David¹  Donadille Cécile²  Ilhame Anwar²  Roux Perrine²  Protopopescu Camelia²  Carrieri Patrizia²  Herin Joris³  Bader Danièle⁴  Pladys Adélaïde⁴ 

[1] AIDES, Pantin, France;Laboratoire de Recherche Communautaire, Coalition PLUS, Pantin, France;Aix Marseille Univ, Inserm, IRD, SESSTIM, Sciences Economiques and Sociales de la Santé and Traitement de l’Information Médicale, ISSPAM, Marseille, France;Bus 31/32, Marseille, France;Coordination Nationale des Réseaux de Microstructures (CNRMS), Strasbourg, France;

关键词: HCV testing;    PWID;    Testing;    Disclosure;    Stigma;   

DOI  :  10.1186/s12954-023-00841-7

 received in 2022-10-06, accepted in 2023-07-22,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundHepatitis C virus (HCV) infection prevalence is particularly high in people who inject drugs (PWID), a population that faces many barriers to HCV testing and care. A better understanding of the determinants of access to HCV testing is needed to improve their engagement in the HCV care cascade. We used data from a cross-sectional survey of people who inject drugs, mainly opioids, to identify factors associated with recent HCV testing.MethodsSelf-reported data on HCV antibody testing were analyzed for 550 of the 557 PWID enrolled in PrebupIV, a French cross-sectional community-based survey which assessed PWID acceptability of injectable buprenorphine as a treatment. Factors associated with recent (i.e., in the previous six months) HCV antibody testing were identified performing multivariable logistic regression.ResultsAmong the study sample, 79% were men and 31% reported recent HCV antibody testing. Multivariable analysis found that PWID who did not disclose their injection practices to anyone (aOR [95% CI] 0.31 [0.12,0.82], p = 0.018), older PWID (aOR [95% CI] 0.97 [0.95,1.00], p = 0.030) and employed respondents (aOR [95% CI] 0.58 [0.37,0.92], p = 0.019) were all less likely to report recent HCV testing. No association was found between opioid agonist therapy and HCV testing.ConclusionsOur findings suggest that non-disclosure of injection practices, employment and age were all barriers to HCV antibody testing. Preventing stigma around injection practices, developing the HCV testing offer in primary care and addiction care services, and training healthcare providers in HCV care management could improve HCV testing and therefore, the HCV care cascade in PWID.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1